BIVI News
Archived Headlines
- US IPO Weekly Recap: The We Company leads the way as the pipeline fills up in a 2-IPO week 08/16/19
- Micro-cap cirrhosis biotech BioVie postpones $15 million IPO 08/12/19
- US IPO Week Ahead: A Kansas bank and a Chinese fintech wrap up the summer IPO market 08/09/19
- Micro-cap cirrhosis biotech BioVie revises terms ahead of $15 million IPO 08/08/19
- US IPO Week Ahead: Summer's last wave with 5 IPOs 08/02/19
See more
US IPO Weekly Recap: Snowflake's IPO breaks records in a diverse 15 IPO week
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the...read more
Micro-cap cirrhosis biotech BioVie prices $16 million Nasdaq uplisting at $10
BioVie, a Phase 2 biotech developing therapies for cirrhosis, raised $16 million by offering 1.6 million shares at $10, below the last close of its shares on the OTC (BIVI). The company offered 0.3 million more shares than anticipated. BioVie plans to list...read more
Micro-cap cirrhosis biotech BioVie removes warrants ahead of $18 million Nasdaq uplisting
BioVie, a Phase 2 biotech developing therapies for cirrhosis, submitted an amendment on Wednesday with the SEC. The blank filing indicates that the company plans to raise up to $18 million in an initial public offering. The company is currently listed on the...read more
Cirrhosis biotech BioVie revives $15 million Nasdaq IPO plans in latest filing
BioVie, an early stage biotech developing therapies for cirrhosis, filed an amended S-1 on Wednesday with the SEC to raise up to $15 million, based on its registered offering of 1.7 million units at $8.75, the as-converted last close of its stock on the OTCQB...read more